Compare Abeona Therapeutics Inc (ABEO) vs F5 Inc (FFIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs F5 Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while F5 Inc trades at $419.14 (market cap $23.53B). The key difference: F5 Inc is far larger — about 63× Abeona Therapeutics Inc's market cap, and F5 Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FFIV | |
|---|---|---|
Market Cap | $373.32M | $23.53B |
Sector | Health | Technology |
52-Week High | $7.23 | $424.18 |
52-Week Low | $4.17 | $223.99 |
Enterprise Value | $228.22M | $22.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
F5 (FFIV) trades at $417.11, up 2.16% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock is technically bullish, trading above key support levels, while fundamentals show robust revenue growth to $3.09B in 2025 and a high net income margin of 21.96%. Recent strategic moves include expanding AI security offerings through acquisitions and partnerships, positioning the company in the high-growth cybersecurity sector.
The outlook remains positive given consistent earnings outperformance and strategic focus on AI security, though valuation multiples like a P/E of 34.42 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $397 price target slightly below current levels, indicating cautious optimism amid growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
